Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

PERSEVERE- A Trial to Evaluate AMDS in Acute DeBakey Type I Dissection

A legfontosabb adatok

Ki végzi
Artivion Inc.
Hol
Ann Arbor, Atlanta, Aurora, Austin, Birmingham, Boston, Charleston, Charlotte, Chicago, Cleveland, Gainesville, Hartford, Houston, Los Angeles, New York, Palo Alto, Philadelphia, Pittsburgh, Plano, Portland, St Louis, The Bronx és Wynnewood (Egyesült Államok)Mind a 25 helyszín megnézése
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
115 fő vett részt
Kezdés
2022. máj. 27.
Várható befejezés
2029. dec. 6.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • AMDS
A regiszteradat frissítve
2025. január 15.

Ki vehet részt

Életkor
18 év – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 35 feltétel megnézéseKevesebb

Ki vehet részt

  • ≥18 years of age or ≤80 years of age (male or female) at time of surgery
  • Acute DeBakey type I dissection based on computed tomography angiography (CTA) and diagnosed ≤14 days from of the index event
  • Presence of malperfusion (cerebral, visceral, renal, spinal cord, and/or peripheral)

Ki nem vehet részt

  • Previous placement of a thoracic endovascular graft
  • Interventional and/or open surgical procedures 30 days prior to the dissection repair
  • Planned major interventional and/or open surgical procedures 30 days post the dissection repair
  • Diagnosed with acute myocardial infarction in the 30 days prior to the dissection diagnosis
  • Diagnosed with severe and catastrophic neurological complications in the 30 days prior to the dissection diagnosis (namely, obtundation or coma)
  • Clinical or radiographic signs of bowel infarction or gastrointestinal hemorrhage
  • Systemic infection
  • Uncontrollable anaphylaxis to iodinated contrast (patients with allergy to iodinated contrast but not anaphylaxis may be eligible with appropriate pre-medication, as deemed suitable by the Investigator)
  • Known allergy(ies) to nitinol and/or polytetrafluoroethylene
  • History of bleeding disorder (i.e. hemophilia)
  • Suspicion of bowel necrosis (as determined by the implanting physician based on imaging observations, peritoneal signs, surgical exploration, elevated serum lactate levels, low pH, and/or acidosis)
  • Base deficit > -10 mmol/L or -10 mEq/L
  • Previously diagnosed with Marfan syndrome, Ehlers-Danlos syndrome, or Loeys-Dietz syndrome based on laboratory genetic testing
  • Current Stage 5 end stage chronic kidney disease (eGFR ≤ 15 mL/min)
  • Other medical condition that is associated with limited life expectancy <2 years (e.g., cancer, congestive heart failure)
  • Pregnant or breastfeeding
  • Unwilling to comply with the follow-up schedule
  • Institutionalized due to administrative or judicial order
  • Unwilling to accept blood transfusions for any reason
  • Coronary malperfusion
  • In circulatory shock (i.e., systolic blood pressure <90 mmHg) at time of screening
  • In extreme hemodynamic compromise requiring cardiopulmonary resuscitation at time of screening
  • American Society of Anesthesiologists risk class V (i.e., moribund patient not expected to live 24 hours with or without operation) or class VI (a declared brain dead patient whose organs are being removed for donor purposes)
  • Inability to obtain CT angiograms for follow-up
  • A primary entry tear that extends into the arch or distal to the left subclavian artery
  • Need for a total aortic arch replacement and/or repair, or reconstruction, of any part of the arch, and branch vessels (including extra-anatomic bypass of the branch vessels), for any reason as deemed necessary by the Investigator
  • Any pathology of mycotic origin
  • Aortic fistulous communication with non-vascular structure (e.g., esophagus, bronchial)
  • Extensive thrombus or calcifications in the aortic arch, as defined by CTA
  • Excessive tortuosity precluding safe passage of the AMDS, as defined by CTA
  • Descending thoracic aneurysm involving the proximal third (one-third) of the descending aorta and measuring >45 mm in diameter
  • Aortic arch aneurysm >50 mm in diameter

Helyszínek itt: Egyesült Államok

  • University of MichiganAnn Arbor, Egyesült Államok
  • Emory University Medical CenterAtlanta, Egyesült Államok
  • University of ColoradoAurora, Egyesült Államok
  • Ascension Seton/University of TexasAustin, Egyesült Államok
  • University of Alabama at BirminghamBirmingham, Egyesült Államok
  • Massachusetts General HospitalBoston, Egyesült Államok
  • Medical University of South CarolinaCharleston, Egyesült Államok
  • Atrium Health - Carolinas Medical CenterCharlotte, Egyesült Államok
  • Northwestern UniversityChicago, Egyesült Államok
  • Cleveland Clinic FoundationCleveland, Egyesült Államok
  • University of FloridaGainesville, Egyesült Államok
  • Hartford HospitalHartford, Egyesült Államok
  • Baylor College of Medicine St. Luke's Medical CenterHouston, Egyesült Államok
  • University of Southern CaliforniaLos Angeles, Egyesült Államok
  • Columbia University Irving Medical Center/New York Presbyterian HospitalNew York, Egyesült Államok
  • Mount Sinai HospitalNew York, Egyesült Államok
  • NorthwellNew York, Egyesült Államok
  • Stanford UniversityPalo Alto, Egyesült Államok
  • University of PennsylvaniaPhiladelphia, Egyesült Államok
  • University of Pittsburgh Medical CenterPittsburgh, Egyesült Államok
  • Baylor Scott & White The Heart Hospital - PlanoPlano, Egyesült Államok
  • Oregon Health and Science UniversityPortland, Egyesült Államok
  • Washington University in St. LouisSt Louis, Egyesült Államok
  • Montefiore Einstein MedicalThe Bronx, Egyesült Államok
  • Lankenau Medical CenterWynnewood, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Prospective, non-randomized, multicenter clinical investigation to assess the safety and effectiveness of AMDS in the treatment of patients with acute DeBakey type I dissection, with evidence of malperfusion, through open surgical repair.

A vizsgálat csoportja

  • Acute DeBakey Type I DissectionA vizsgált kezelés

    In eligible patients, the ascending aorta is transected and removed in a routine standard of care manner utilizing hypothermic circulatory arrest; the operator will leave at least 10 mm (1.0 cm) aortic tissue proximal to the innominate artery. AMDS is pre-loaded onto the delivery system and is delivered into the true lumen through the open distal aorta and implanted according to the instructions for use.

    Kezelés: AMDS

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A ProspEctive, Single ARm, Multi-center Clinical InveStigation to EValuatE the Safety and Effectiveness of AMDS in the TREatment of Acute DeBakey Type I Dissection: PERSEVERE
Publikációk
A regiszteradat frissítve
2025. január 15.